Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms 7E11-C5.3-meO- DOTA-177Lu, Anti-PSMA-meO-DOTA-177Lu, 177LU-7E11.C5.3 + [2] |
Target |
Action inhibitors |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 1 | United States | 01 Feb 2007 | |
Metastatic Prostate Carcinoma | Phase 1 | United States | 01 Feb 2007 |